Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. - Wikidata - wikimedia - TriplyDB

Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.

Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.

http://www.wikidata.org/entity/Q34620664

about

Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen.Clinical predictive models for chemotherapy-induced febrile neutropenia in breast cancer patients: a validation study.The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for hu Innate immune regulation by STAT-mediated transcriptional mechanisms.Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland.Clinical practice in secondary prophylaxis and management of febrile neutropenia in Poland: results of the febrile neutropenia awareness project.Febrile neutropenia in chemotherapy treated small-cell lung cancer patients Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy.Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?The importance of supportive care in optimizing treatment outcomes of patients with advanced prostate cancer.Neutropenia and G-CSF in lymphoproliferative diseases.Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia Bloodstream infections in neutropenic cancer patients: A practical update.Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice Impact of Guidance on the Prescription Patterns of G-CSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population-Based Utilization Study in the Lazio Region.Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors.Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.Adjuvant systemic treatment for elderly breast cancer patients; addressing safety concerns.Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.Efficacy and safety of biosimilar filgrastim in primary and secondary prevention of febrile neutropenia Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.Bloodstream infections in patients with solid tumors.Supportive Care in Older Adults with Cancer: Across the Continuum.Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.Granulocyte growth factor use in elderly patients with non-Hodgkin's lymphoma in the United States: adherence to guidelines and comparative effectiveness.Characterization of Guideline Evidence for Off-label Medication Use in the Intensive Care Unit.The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum.

P2860

Q24198118-429B81D5-5DC5-4A4D-BDA3-DCDA968E1D24 Q26749476-05123278-02B7-49C3-9516-6FF24A978DA4 Q27008080-663EC38A-5729-4B78-9823-8754053C4418 Q30975418-B289AC45-A28F-4BDE-87F0-3B2E88C06A5D Q33413142-C9915DA5-2CB3-47D5-B4AC-A21670A340CC Q33414659-77EA49B3-B26B-43C6-98A5-458A77074EFE Q33778817-B715DE72-5312-4E1D-AB53-179E52BD454F Q33829742-61A689CB-505E-4B1C-8719-57313E5151DA Q34055968-358C1444-96E3-4EBB-ABB8-0F1F2164D289 Q35123683-DA9425C3-F07A-401F-917E-B3139FE51ABF Q35165571-A9DAD47C-5E6B-4828-BE72-8BB2C970542D Q35165579-0EB18E50-91D1-48F5-BB0B-AD7AF863D4BB Q35297079-B607AEEE-9304-4CB4-9AD2-BAB98C8A4800 Q35303471-0016BB33-FB58-4016-A9DD-C0DE4AF99872 Q35811836-C187D0D1-9FF6-44FF-9DE2-C89E382BE5C3 Q36023851-33075FA8-D33D-4FAE-8912-55D7A06099A9 Q36672788-D85B85E6-066F-4B0F-8CD2-39F6ECACA412 Q36828921-EB4FA550-16D0-40E5-85AC-EAD294C9C41E Q36897773-945812B5-F09F-4A14-9379-EBC1142EFA55 Q36913345-73D1CFBF-509E-4D79-9598-0807E74A6E4D Q37072872-F8D4FC52-4FD1-430C-865A-17831E515CA7 Q37373201-73D125B5-FE1D-4E89-90AF-CFB63955D837 Q37554901-2BF7F7E9-E860-4CC3-8577-654957DACFA3 Q37737572-68691AF9-45CF-43B5-9CBB-3852D6E17D0D Q37931905-1C1D9917-BDD5-49BF-A222-41E49DF58BAC Q38225700-91B42F0D-0E35-4770-A51B-B69F387AD764 Q38253136-6762A113-3F52-4F64-97C7-77318F402368 Q38256944-B9A7986C-3757-47C7-8131-A9F4ED223FD2 Q38405004-45F02633-95BB-423A-93B6-CBF079FA10DE Q38580333-C1C85804-8E10-4FD1-969B-97C44740A8FB Q38613025-59FBF408-82F9-4000-8C1B-A058B6835A9C Q38626569-A69AEAE7-E7BB-42E7-A65F-C8AFB97DC513 Q38682028-C5C5B60B-4F74-4848-9D4B-F322EC479AF4 Q38703440-9AE3E352-59E8-4157-A087-43529B655314 Q38876363-A9DA818A-2848-4FEC-8165-4A45863877A8 Q38940016-CF74E669-8E12-4568-BBAA-31E50EC90222 Q40094120-A3E830EB-85BA-4C0B-92C6-E071D9144B93 Q40121607-9859C2A8-0DA5-4E53-BC38-1902EE31DE3A Q40156982-6A5F40F9-8DBF-4AF2-BCBE-DFC83C24B11D Q40222201-9C485547-529A-4CFA-85A6-D773FD4EC197

P2860

Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.

http://www.wikidata.org/entity/Q34620664

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.

@ast

Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.

@en

Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.

@nl

type

label

Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.

@ast

Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.

@en

Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.

@nl

prefLabel

Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.

@ast

Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.

@en

Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.

@nl

P1433

Q34620664-9EAF6407-BB0A-434D-B743-F1827E646A6B

P1476

Q34620664-8F519C22-71F4-4F24-BAC2-D96BE97541E7

P2093

Q34620664-5AC33860-002E-4C2B-B572-35B8503964F8

Q34620664-6A079E0B-F881-44EC-8F99-BE5510F31AE7

Q34620664-755384B3-0215-4BB0-ACF3-6C9A01B0A662

Q34620664-B2466083-D2B5-4B15-AEEA-D843552D1765

P2860

Q34620664-358F04F5-DF7C-4BA0-BC96-20E06A944635

Q34620664-3591C9E6-B137-4D19-897D-4B1BCAD432FE

Q34620664-3C4E119F-EA47-4C9C-965F-1AC308FD5CC7

Q34620664-3CA36B35-577F-47DE-9559-6CE362972226

Q34620664-5614ED43-07CF-431C-B776-769D5D6AB42E

Q34620664-775812C7-0DC4-4C83-8297-6649EDE0B3F0

Q34620664-7A1875CE-3E95-4756-B345-50389580A5E8

Q34620664-88CA87F4-9B54-41B0-BA8D-D08026CB4341

Q34620664-8CA7EDC7-EDD1-47F2-8597-1A32B68F5D62

Q34620664-A70628EB-2E8B-4F98-B5ED-0B2F4E7F4BEA

P304

Q34620664-DEE35983-44C4-468D-93D5-34715BF9279C

P31

Q34620664-129CA303-5B2B-4DDA-89EC-E0FF38962D3C

P356

Q34620664-ED9B5A28-530C-4B64-9295-FE108C22C2C2

P478

Q34620664-AF5E2094-C925-4F8E-A9CE-8079A01E8DA7

P577

Q34620664-F743CA2A-AEB4-49AC-A4A6-239582842170

P5875

Q34620664-767FF9DB-E414-4525-9357-A6469713D0F5

P698

Q34620664-36D90372-1D48-4FDB-9089-9F77CFE061D3

P356

P1433

Annals of Oncology

P1476

Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.

@en

P2093

C Caserta

http://www.w3.org/2001/XMLSchema#string

ESMO Guidelines Working Group

http://www.w3.org/2001/XMLSchema#string

F Roila

http://www.w3.org/2001/XMLSchema#string

J Crawford

http://www.w3.org/2001/XMLSchema#string

P2860

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.

Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection.

Canadian supportive care recommendations for the management of neutropenia in patients with cancer.

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients.

Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide follow

Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.

Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group.

P304

v248-51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDQ195

http://www.w3.org/2001/XMLSchema#string

P478

21 Suppl 5

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51443575

http://www.w3.org/2001/XMLSchema#string

P698

20555091

http://www.w3.org/2001/XMLSchema#string